Stephen F. Betz - Mar 4, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Scientific Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Stock symbol: CRNX
Transactions as of: Mar 4, 2024
Transactions value $: $0
Form type: 4
Date filed: 3/6/2024, 07:57 PM
Previous filing: Jan 26, 2024
Next filing: Mar 20, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Award	$0	+23K	+31.38%	$0.00	96.3K	Mar 4, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (right to buy)	Award	$0	+87K		$0.00	87K	Mar 4, 2024	Common Stock	87K	$43.51	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025.
F2	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024.